[Study on the efficacy of combination therapy with rifaximin and Saccharomyces boulardii CNCM I-745 in patients with small intestinal bacterial overgrowth associated with long-term use of proton pump inhibitors].
- 2025-08-28
- RCT · n = 108
- Terapevticheskii arkhiv 97(8)
- I V Maev
- D N Andreev
- R I Shaburov
- A V Zaborovsky
- A K Fomenko
- P S Sokolov
- S V Tsaregorodtsev
- M K Devkota
- D T Dicheva
- S V Cheremushkin
- N V Cheremushkinа
- A V Vychkin
- PubMed: 40884341
- DOI: 10.26442/00403660.2025.08.203301
- High evidence
- Large Human Trial
- Clinical
At 4-week follow-up, repeat lactulose HMBT showed SIBO persistence in 41.5% of Group 1 (n = 22/53) versus 21.8% in Group 2 (n = 12/55; p = 0.038).
- Effect
- Beneficial
- Effect size
- Moderate
- Significant
- Yes
- Dose
- 500 mg twice daily